tirzepatide sodium (sodium salt) | C225H349N48NaO68 | CID 172874756 Tirzepatide 60mg (20mg/mL + Methylcobalamin

Weekly administration formats demonstrate better adherence than daily regimens

Baby was checked this morning, and baby is going good!

On December 20, 2024, Eli Lilly's self-developed GIP/GLP-1 receptor dual agonist tirzepatide injection, Zepbound, received approval from the US FDA for the indication of "treating obstructive sleep apnea (OSA)." It became the first drug approved to directly treat this common sleep disorder and also marked the second indication approved for Zepbound in the United States.

2 About Wegovy Wegovy (semaglutide) injection 2.4 mg is currently approved along with a reduced calorie diet and increased physical activity, for adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off and to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and either obesity or overweight

Practical Considerations for Patients Comfort and Tolerance Modern needles for GLP-1 agents are very fine and short, designed to minimise pain

Most notably, the loss of lean muscle mass along with fat